Newer intranasal migraine medications

Two new intranasal migraine medications, sumatriptan and dihydroergotamine mesylate, may offer specific advantages for patients who are seeking altern atives to various oral or parenteral migraine abortive therapies. Placebo-c ontrolled clinical studies demonstrate that both intranasal forms are effec tive in relieving migraine headache pain, but published clinical trial info rmation comparing these two intranasal medications with current abortive th erapies is lacking. Both agents are generally well tolerated by patients, w ith the exception of mild, local adverse reactions of the nose and throat.